These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 19568080)

  • 21. Successful treatment of Raynaud's phenomenon and digital ulcers in systemic sclerosis patients with botulinum toxin B injection: Assessment of peripheral vascular disorder by angiography and dermoscopic image of nail fold capillary.
    Motegi SI; Sekiguchi A; Saito S; Ishibuchi H; Kishi C; Yasuda M; Ishikawa O
    J Dermatol; 2018 Mar; 45(3):349-352. PubMed ID: 29164658
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The novel use of botulinum toxin A for the treatment of Raynaud's phenomenon in the toes.
    Dhaliwal K; Griffin M; Denton CP; Butler PEM
    BMJ Case Rep; 2018 Mar; 2018():. PubMed ID: 29525756
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of botulinum toxin in vasospastic disorders of the hand.
    Neumeister MW
    Hand Clin; 2015 Feb; 31(1):23-37. PubMed ID: 25455354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Botulinum Toxin for the Treatment of Intractable Raynaud Phenomenon.
    Gallegos JE; Inglesby DC; Young ZT; Herrera FA
    J Hand Surg Am; 2021 Jan; 46(1):54-59. PubMed ID: 32948347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ischaemic ulcers on the toes secondary to Raynaud phenomenon in a patient with systemic sclerosis successfully treated with botulinum toxin.
    Garrido-Ríos AA; González-Olivares M; Navarro-Vidal B; Martínez-Morán C; Borbujo J
    Clin Exp Dermatol; 2018 Jun; 43(4):503-505. PubMed ID: 29274125
    [No Abstract]   [Full Text] [Related]  

  • 26. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
    Colakoğlu M; Cobankara V; Akpolat T
    Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Raynaud's phenomenon of the nipple: a treatable cause of painful breastfeeding.
    Anderson JE; Held N; Wright K
    Pediatrics; 2004 Apr; 113(4):e360-4. PubMed ID: 15060268
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Laser Doppler skin perfusion pressure in the assessment of Raynaud's phenomenon.
    Kanetaka T; Komiyama T; Onozuka A; Miyata T; Shigematsu H
    Eur J Vasc Endovasc Surg; 2004 Apr; 27(4):414-6. PubMed ID: 15015193
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ischemic ulcers of the toes secondary to Raynaud's phenomenon in a child successfully treated with botulinum toxin.
    Quintana Castanedo L; Feito Rodríguez M; Maseda Pedrero R; Chiloeches Fernández C; de Lucas Laguna R
    Pediatr Dermatol; 2020 Jul; 37(4):681-683. PubMed ID: 32212180
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Botulinum toxin-A for the treatment of Raynaud syndrome.
    Smith L; Polsky D; Franks AG
    Arch Dermatol; 2012 Apr; 148(4):426-8. PubMed ID: 22508867
    [No Abstract]   [Full Text] [Related]  

  • 31. A case report of the beneficial effects of botulinum toxin type A on Raynaud phenomenon in a patient with lung cancer.
    Wang L; Lei QS; Liu YY; Song GJ; Song CL
    Medicine (Baltimore); 2016 Oct; 95(40):e5092. PubMed ID: 27749585
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacotherapy of Raynaud's phenomenon.
    Belch JJ; Ho M
    Drugs; 1996 Nov; 52(5):682-95. PubMed ID: 9118818
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Botulinum Toxin in the Long-Term Treatment of Refractory Raynaud’s Phenomenon.
    Asad U; Austin B; Tarbox M; Paulger B
    J Drugs Dermatol; 2019 Sep; 18(9):943-945. PubMed ID: 31524993
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of Botulinum Toxin B Injection for Raynaud's Phenomenon and Digital Ulcers in Patients with Systemic Sclerosis.
    Motegi SI; Uehara A; Yamada K; Sekiguchi A; Fujiwara C; Toki S; Date Y; Nakamura T; Ishikawa O
    Acta Derm Venereol; 2017 Jul; 97(7):843-850. PubMed ID: 28358168
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reactive hyperemia in Raynaud's disease.
    Pratesi F; Corsi C; Deidda C; Nuti A
    Biochem Exp Biol; 1977; 13(3):337-9. PubMed ID: 16296018
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Continuous regional anesthesia before surgical peripheral sympathectomy in a patient with severe digital necrosis associated with Raynaud's phenomenon and scleroderma.
    Greengrass RA; Feinglass NG; Murray PM; Trigg SD
    Reg Anesth Pain Med; 2003; 28(4):354-8. PubMed ID: 12945033
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Minimally invasive treatment of Raynaud phenomenon: the role of botulinum type A.
    Neumeister MW; Webb KN; Romanelli M
    Hand Clin; 2014 Feb; 30(1):17-24. PubMed ID: 24286738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Laser Doppler-recorded venoarteriolar reflex in Raynaud's phenomenon.
    Stoyneva Z
    Auton Neurosci; 2004 Nov; 116(1-2):62-8. PubMed ID: 15556839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Improvement of idiopathic Raynaud's phenomenon following local infusion of botulinum toxin].
    Roguedas AM; Misery L
    Ann Dermatol Venereol; 2014; 141(6-7):462-3. PubMed ID: 24951147
    [No Abstract]   [Full Text] [Related]  

  • 40. The Role of Botulinum Toxin A in the Treatment of Raynaud Phenomenon.
    Segreto F; Marangi GF; Cerbone V; Persichetti P
    Ann Plast Surg; 2016 Sep; 77(3):318-23. PubMed ID: 26808752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.